Latest news with #BIOA
Business Insider
5 days ago
- Health
- Business Insider
BioAge Labs announces it will present new preclinical data on APJ agonism
BioAge Labs (BIOA) announced that it will present new preclinical data supporting apelin receptor, APJ, agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction. The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20-23, 2025, in Chicago, Illinois. In their two presentations, the company will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies. Enhanced glycemic control in diabetic obesity – Dr. Rubin's oral presentation will show that in mouse models of diabetic obesity, APJ agonist monotherapy reduced HbA1c to levels comparable to lean controls and improved glucose tolerance by 25%. Cardioprotective effects in HFpEF – Dr. Yan's poster will show that in a mouse model of obesity-associated heart failure, APJ agonist monotherapy reduced cardiac hypertrophy and suppressed markers of cardiac injury. Combination of APJ agonism with an incretin provided enhanced cardioprotective benefits and greater weight loss compared to either treatment alone. Confident Investing Starts Here:
Yahoo
30-05-2025
- Business
- Yahoo
BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025
BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies for its groundbreaking oral NLRP3 inhibitor, BGE-102, targeting obesity. The company plans to submit an Investigational New Drug (IND) application by mid-2025, with first Phase 1 single ascending dose (SAD) data expected by year-end. A scientist in a lab coat analyzing samples from a petri dish, studying the effects of a potential drug candidate. BGE-102, an internally discovered compound, is distinguished by its novel binding site, high potency, and brain penetration. In preclinical obesity models, BGE-102 delivered dose-dependent weight loss comparable to leading GLP-1 agonist semaglutide, achieving up to 15% reduction as monotherapy and over 20% when combined with semaglutide. The drug also improved insulin sensitivity and demonstrated a robust safety margin in toxicology studies. BioAge Labs, Inc. (NASDAQ:BIOA)'s CEO, Kristen Fortney, Ph.D., highlighted BGE-102's potential as a once-daily oral therapy, either alone or with GLP-1 receptor agonists, by targeting the NLRP3 inflammasome, a key driver of inflammation and metabolic dysfunction in obesity. Pending IND clearance, BioAge Labs, Inc. (NASDAQ:BIOA) will launch Phase 1 trials, with a Phase 1b proof-of-concept study in obesity planned for late 2026. While we acknowledge the potential of BIOA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIOA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-04-2025
- Business
- Yahoo
BioAge Labs, Inc. (BIOA): A Bull Case Theory
We came across a bullish thesis on BioAge Labs, Inc. (BIOA) on Substack by Ragnarok Research. In this article, we will summarize the bulls' thesis on BIOA. BioAge Labs, Inc. (BIOA)'s share was trading at $3.87 as of April 17th. A biopharmaceutical laboratory with researchers at work analyzing complex molecules. BioAge Labs (BIOA) represents a classic "cigarette butt" investment—an overlooked and beaten-down company that still has a few valuable puffs left. Following the abrupt halt of its STRIDES Phase 2 clinical trial for the obesity drug Azelaprag in December 2024, due to elevated liver enzymes in several patients, shares collapsed by over 76%. This sharp decline led investors to assume the company had no remaining value. However, BioAge retains meaningful worth both in its balance sheet and in the long-term potential of its income statement. The market's overreaction has created a significant mispricing. With limited downside and credible hidden value, it fits the mold of a cigar butt stock—one discarded by the market but still capable of delivering strong returns. The investment case is based on the belief that BioAge's current valuation ignores both its asset base and future income potential, with a price target of $7 per share reflecting its true worth. BioAge Labs, Inc. (BIOA) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 13 hedge fund portfolios held BIOA at the end of the fourth quarter which was 17 in the previous quarter. While we acknowledge the risk and potential of BIOA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than BIOA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
Associated Press
07-03-2025
- Business
- Associated Press
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge Labs, Inc. (BIOA) Shareholders
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioAge Labs, Inc. ('BioAge' or the 'Company') (NASDAQ: BIOA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioAge investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024. Follow the link below to get more information and be contacted by a member of our team: BIOA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024. WHAT'S NEXT? If you suffered a loss in BioAge during the relevant time frame, you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Tel: (212) 363-7500 Fax: (212) 363-7171
Associated Press
10-02-2025
- Business
- Associated Press
Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for Investors – Contact Levi & Korsinsky
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioAge Labs, Inc. ('BioAge' or the 'Company') (NASDAQ: BIOA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioAge investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26, 2024. Follow the link below to get more information and be contacted by a member of our team: BIOA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024. WHAT'S NEXT? If you suffered a loss in BioAge during the relevant time frame, you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004
